Transgene Presents 2018 Half-Year Results and Business Update

information fournie par Boursorama •19/09/2018 à 17:45

Transgene Presents 2018 Half-Year Results and Business Update


- Transgene obtains $48 million in Tasly Biopharmaceuticals shares with the sale of the Greater China rights of TG1050 and TG6002
- Key trials of Transgene’s immunotherapeutics to deliver results before the end of 2018 and over the course of 2019
- Strong research capabilities put Company at the forefront of innovation
*Oncolytic virus Invir.IOTM platform progressing well
*An ambitious personalized therapeutic vaccine platform to be presented in the coming weeks
- €33.0 million in cash and cash equivalents providing financial visibility until the end of September 2019
.../...